We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion in cash, in a deal that would give it ...

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilars to market, in a bid to accelerate the rollout of cheaper versions of off-patent biologic drugs. Draft ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Prostate Cancer UK started a £42 million ($55 million), large-scale study called TRANSFORM last year to test that MRI-refined ...

At San Diego-based CDMO and CRO Abzena, Geoffrey M Glass has stepped into the CEO role. Glass has served as Chairman of the ...

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at developing it as a partner drug to Keytruda. The combination has been approved for ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG), which is impaired in LGMD and causes muscle wasting, initially in the ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

At ESMO this year, AstraZeneca presented final overall survival results from the MATTERHORN Phase III Trial for patients with ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...